Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Change in Accured Expenses (2017 - 2022)

Historic Change in Accured Expenses for Arcus Biosciences (RCUS) over the last 6 years, with Q3 2022 value amounting to $23.5 million.

  • Arcus Biosciences' Change in Accured Expenses rose 16922.19% to $23.5 million in Q3 2022 from the same period last year, while for Sep 2022 it was $4.2 million, marking a year-over-year decrease of 5434.85%. This contributed to the annual value of $10.1 million for FY2021, which is 2618.86% down from last year.
  • According to the latest figures from Q3 2022, Arcus Biosciences' Change in Accured Expenses is $23.5 million, which was up 16922.19% from -$1.8 million recorded in Q2 2022.
  • Arcus Biosciences' Change in Accured Expenses' 5-year high stood at $23.5 million during Q3 2022, with a 5-year trough of -$9.9 million in Q4 2020.
  • Its 5-year average for Change in Accured Expenses is $2.1 million, with a median of $1.6 million in 2019.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first skyrocketed by 120904.76% in 2018, then tumbled by 70535.28% in 2020.
  • Arcus Biosciences' Change in Accured Expenses (Quarter) stood at -$2.3 million in 2018, then surged by 45.61% to -$1.2 million in 2019, then plummeted by 705.35% to -$9.9 million in 2020, then grew by 9.11% to -$9.0 million in 2021, then soared by 359.94% to $23.5 million in 2022.
  • Its last three reported values are $23.5 million in Q3 2022, -$1.8 million for Q2 2022, and -$8.5 million during Q1 2022.